All patients
Age < 65y (younger) Age > 65y Asian type cancer location (esophagus) cancer location (gastro-esophageal) cell type, adenocarcinoma cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male HER2 negative HER2 positive metastasis (lymph node ) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% smoker (Current) smoker (Former) smoker (never) stage II stage III (locally advanced)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
esophageal cancer (EC), anti-PD-(L)1 vs. placebo, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias events or deaths (EFS)detailed results CheckMate 577, 2021 0.63 [0.46; 0.86]
0.63 [0.46 ; 0.86 ] CheckMate 577, 2021 1 0% 794 NA not evaluable AE (any grade)detailed results CheckMate 577, 2021 1.81 [0.96; 3.41]
1.81 [0.96 ; 3.41 ] CheckMate 577, 2021 1 0% 794 NA not evaluable AE (grade 3-4)detailed results CheckMate 577, 2021 1.10 [0.80; 1.51]
1.10 [0.80 ; 1.51 ] CheckMate 577, 2021 1 0% 792 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results CheckMate 577, 2021 1.76 [1.04; 2.97]
1.76 [1.04 ; 2.97 ] CheckMate 577, 2021 1 0% 792 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 577, 2021 1.17 [0.64; 2.15]
1.17 [0.64 ; 2.15 ] CheckMate 577, 2021 1 0% 792 NA not evaluable SAE (any grade)detailed results CheckMate 577, 2021 0.99 [0.71; 1.36]
0.99 [0.71 ; 1.36 ] CheckMate 577, 2021 1 0% 792 NA not evaluable SAE (grade 3-4)detailed results CheckMate 577, 2021 0.98 [0.68; 1.42]
0.98 [0.68 ; 1.42 ] CheckMate 577, 2021 1 0% 792 NA not evaluable STRAE (any grade)detailed results CheckMate 577, 2021 2.94 [1.30; 6.65]
2.94 [1.30 ; 6.65 ] CheckMate 577, 2021 1 0% 792 NA not evaluable STRAE (grade 3-4)detailed results CheckMate 577, 2021 4.94 [1.49; 16.37]
4.94 [1.49 ; 16.37 ] CheckMate 577, 2021 1 0% 792 NA not evaluable TRAE (any grade)detailed results CheckMate 577, 2021 3.12 [1.46; 6.71]
3.12 [1.46 ; 6.71 ] CheckMate 577, 2021 1 0% 792 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 577, 2021 1.86 [0.80; 4.34]
1.86 [0.80 ; 4.34 ] CheckMate 577, 2021 1 0% 792 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 18:47 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 78,230,231,149,151,150,148
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563